Lymphohistiocytic hemophagocytosis

Macrophage activation syndrome (MAS) is a rare clinical biological and cytological entity that can be life-threatening. It is a state of complex immune and hyper-inflammatory dysregulation characterized by excessive and inappropriate activation of macrophages and the lymphoid system associated with organ infiltration and uncontrolled hypercytokinemia leading to uncontrolled hemophagocytosis. Early diagnosis and therapeutic management improve the overall prognosis of MAS. The aims of this study were to describe the epidemiological clinico-biological cytological etiological therapeutic and evolutionary characteristics of patients with secondary MAS.